Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

783.18 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 692
Open 783.18
Bid (Size) 784.00 (1)
Ask (Size) 788.00 (5)
Prev. Close 783.18
Today's Range 783.18 - 783.18
52wk Range 434.34 - 800.78
Shares Outstanding N/A
Dividend Yield 0.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
HIMS stock is catching a bid after Hims & Hers announced that it would begin providing access to GLP-1 weight-loss injections. 
Via InvestorPlace
Here's How Much $100 Invested In Eli Lilly and Co 5 Years Ago Would Be Worth Today
Via Benzinga

Performance

YTD
+32.25%
+32.25%
1 Month
+7.09%
+7.09%
3 Month
+3.64%
+3.64%
6 Month
+31.05%
+31.05%
1 Year
+72.53%
+72.53%

More News

Read More
Magnificent Seven? Just Two Members Meet This Earnings Criteria
Via Investor's Business Daily
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Via The Motley Fool
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
Via Benzinga
Topics ETFs
Evaluating Eli Lilly and Co Against Peers In Pharmaceuticals Industry
Via Benzinga
Is Eli Lilly's Latest Deal a Gamechanger?
Via The Motley Fool
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Via InvestorPlace
Rally Rockets: 3 Stocks Benefitting From the Market’s Unstoppable Surge
Via InvestorPlace
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Via News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Via The Motley Fool
3 Stocks To Buy Following Positive Earnings Results
Via Talk Markets
Topics Stocks
Exposures US Equities
Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show
Via Benzinga
The Dividend Investor’s Playbook: 3 Stocks for Consistent Cash Flow in 2024
Via InvestorPlace
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
These 2 No-Brainer Growth Stocks Are Breaking New Ground
Via The Motley Fool
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Wall Street Favorites: 3 Growth Stocks With Strong Buy Ratings for May 2024
Via InvestorPlace
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Via Benzinga
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Via Benzinga
These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now
Via The Motley Fool
2 Top Pharma Stocks That Just Keep Getting Better and Better
Via The Motley Fool
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene
Via InvestorPlace
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.